$Pistol Pete$, $Mick$ & Friends Stock Picks /news, DD and charts

[123414]

The performance report aligns pretty well with the stock history of rapid recovery after a Public Placement when PPS reach the current area.
The company is now funded and are in the Heads down mode. They are quietly exacuating necessary steps for further PHASE 2 Bladder cancer trial/treatments/advancements. The first patient for Phase 2 has already been treated, with more patients to be treated this year.

The results from the completed Phase 1 study were excellent with patient 5 cancer free after 18 months and patient 6 unreported at 18 months but cancer free at 12 months. Further the safety ratings for the studies are very good, maintaining a very sufficient competitive advantage.

_____________________________________________

TLTFF has a history of bouncing back from these levels.

Many solid catalysts are near term.

Phase 1 patient 6 data.

Phase 2 patient treatments

Phase 2 FDA submissions.

The company has money in the bank to execute all of the objectives.

Looking at the 5 year chart one can see the explosive returns associated with these price levels. These price levels are associated with cash grabs to fund operations.

https://www.barchart.com/stocks/quotes/TLTFF/technical-chart?plot=HLWCDL&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=BBANDS(20,2);KELT(20);ACCUM;MACD(12,26,9)&sym=TLTFF&grid=1&height=500&studyheight=100 (link to 5 year chart)

https://theralase.com/press-releases/ (link to PRs)

Current price below .20 with a buy rating and Price target of .60 USD
_________________________________

Globe says Mackie rates Theralase "speculative buy"
TLTFF Speculative buy rating-Target price .60USD / .80CAD

TLTFF 0.1827USD (+0.94%) 20/SEPT/19

2019-09-19 07:20 ET - In the News

The Globe and Mail reports in its Thursday, Sept. 19, edition that Mackie Research analyst Andre Uddin began coverage of Theralase Technologies (23.5 cents) with a "speculative buy" rating and 80-cent-CAD share target. The Globe's David Leeder writes in the Eye On Equities column that Mr. Uddin says in a note: "Theralase is focused on developing a paradigm-shifting Photodynamic Therapy (PDT) for treating Bacillus Calmete Guerin (BCG) -- unresponsive non-muscle invasive bladder cancer (NMIBC) -- targeting a significant market opportunity and unmet medical need (the only currently approved treatment option for patients is to have their bladder removed surgically or use Valrubicin). Theralase has completed a single-arm Phase Ib trial in 6 BCG-unresponsive NMIBC subjects. At the therapeutic dose, PDT induced a durable 67-per-cent Complete Response (CR) rate after one year -- far surpassing CR and duration of CR results of other bladder cancer treatment modalities, currently in development. Results to date have shown that Theralase's PDT was safe, well tolerated and at the therapeutic dose, effective, compared to other competitive drugs in development."
© 2019 Canjex Publishing Ltd. All rights reserved.

https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aTLT-2811319&symbol=TLT®ion=C